<DOC>
	<DOCNO>NCT01127438</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy LUSEDRA ( fospropofol disodium ) determine whether dose low currently approve provide effective moderate sedation require complete diagnostic therapeutic procedure .</brief_summary>
	<brief_title>A Dose-ranging Study Evaluate Safety Efficacy LUSEDRA ( Fospropofol Disodium ) Intravenous Sedative Diagnostic Therapeutic Colonoscopy Adult Special Populations</brief_title>
	<detailed_description>This double-blind , randomize , parallel-group , multicenter , dose-ranging study , age &gt; /= 65 year , and/or weight &lt; 60 kg , and/or American Society Anesthesiologists ( ASA ) Physical Classification Status 3 4 subject use either approve dose modification 1 low dose , achieve moderate level sedation require complete schedule diagnostic therapeutic procedure . Three subgroup subject include . For Subgroup 1 Subgroup 2 , approximately equal number subject enrol 2 stratum : weight &gt; /= 55 kg weight &lt; 55 kg . For Subgroup 1 Subgroup 2 , subject randomly assign 1 2 dose group 1:1 ratio within stratum . For Subgroup 3 , subject randomly assign 1 2 dose group 1:1 ratio .</detailed_description>
	<mesh_term>Hypnotics Sedatives</mesh_term>
	<mesh_term>Fospropofol</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<criteria>Subjects meet follow criterion include study : 1 . Male female adult candidate diagnostic therapeutic colonoscopy least one follow characteristic : Subgroup 1 : Weight &lt; 60 kg age &gt; /= 18 &lt; 65 year ASA I II ; Subgroup 2 : Weight &lt; 60 kg age &gt; /= 65 year and/or ASA 3 4 ; Subgroup 3 : Weight &gt; /=60 kg age &gt; /= 65 year and/or ASA 3 4 . 2 . Females childbearing potential must negative beta human chorionic gonadotropin ( ? hCG ) urine pregnancy test Visit 1 ( Screening ) prior start study drug ( Visit 2 ) . Female subject childbearing potential must agree abstinent use highly effective method contraception ( eg , condom + spermicide , condom + diaphragm spermicide , intrauterine device [ IUD ] , vasectomise partner ) start least 1 menstrual cycle prior start study drug throughout entire study period 30 day last dose study drug . Those woman use hormonal contraceptive must also use additional approve method contraception ( describe previously ) . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ; 3 . Are willing able comply aspect protocol ; 4 . Provide write informed consent . Subjects meet follow criterion exclude participation study : 1 . Females pregnant ( positive BhCG urine pregnancy test ) breastfeeding ; 2 . Subjects meet nil per o ( NPO ) requirement solid food within 8 hour clear fluid 3 hour procedure ( assessed Baseline ) ; 3 . Evidence clinically significant disease history concomitant medical condition ( eg , cardiac , respiratory , gastrointestinal , renal disease ) , opinion Investigator , could affect subject 's safety ability safely complete study ; 4 . Subjects hypersensitivity LUSEDRA component LUSEDRA , include active metabolite , propofol ; 5 . History drug alcohol dependency abuse within approximately last 2 year ; 6 . The Investigator believe medically unfit receive study drug unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Monitored anesthesia care sedation</keyword>
</DOC>